Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/brisbane/02/2018 (h1n1)-pdm09: reassortanten virus ivr-190, abgeleitet von a/brisbane/02/2018), haemagglutininum influenzae a (h3n2) (virus-souche a/kansas/14/2007 (h3n2)-like: reassortanten virus nymc x-327, abgeleitet von a/kansas/14/2017), haemagglutininum influenzae b (virus-souche b/colorado/06/2017 (victoria-linie)-wie: reassortanten virus nymc bx-69a, abgeleitet von b/maryland/15/2016) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus-souche a/brisbane/02/2018 (h1n1)-pdm09: reassortanten virus ivr-190, abgeleitet von a/brisbane/02/2018) 15 µg, haemagglutininum influenzae a (h3n2) (virus-souche a/kansas/14/2007 (h3n2)-like: reassortanten virus nymc x-327, abgeleitet von a/kansas/14/2017) 15 µg, haemagglutininum influenzae b (virus-souche b/colorado/06/2017 (victoria-linie)-wie: reassortanten virus nymc bx-69a, abgeleitet von b/maryland/15/2016) 15 µg, haemagglutininum influenzae b (virus-souche b/phuket/3073/2013 (yamagata-linie)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, wasser ad iniectabilia q.s. zu der suspension mit 0,5 ml, der rest: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortanten virus a/brisbane/02/2018, ivr-190), haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortanten virus a/kansas/14/2017, nymc x-327), haemagglutininum influenzae b (virus-stamm b/colorado/06/2017-wie: reassortanten virus b/maryland/15/2016 nymc bx-69a) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortant virus a/brisbane/02/2018, ivr-190) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortant virus a/kansas/14/2017, nymc x-327) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: natrii citras dihydricus max. 1 mg, cetrimidum max. 15 µg, formaldehydum max. 10 µg, gentamicini sulfas max. 1 ng, tylosini tartras nihil, hydrocortisonum nihil, polysorbatum 80 nihil, ovalbuminum max. 0.1 µg, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab dem vollendeten 6. lebensmonat - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/guangdong-maonan/swl1536/2019 (h1n1)-like: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus nib-121 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/guangdong-maonan/swl1536/2019 (h1n1)-like: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus nib-121 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 3 jahren - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-224 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-224 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 6 monaten - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/darwin/9/2021 (h3n2)-like: reassortant virus derived from a/darwin/9/2021, san-010), haemagglutininum influenzae b (virus-stamm b/austria/1359417/2021 -like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/darwin/9/2021 (h3n2)-like: reassortant virus derived from a/darwin/9/2021, san-010) 15 µg, haemagglutininum influenzae b (virus-stamm b/austria/1359417/2021 -like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 6 monaten - impfstoffe